On Wednesday, Shares of Calpine Corporation (NYSE:CPN), gained 0.12% to $16.24.
Calpine Corporation, declared that it has agreed to acquire the Granite Ridge Energy Center from Granite Ridge Holdings, LLC for $500 million, or about $671 per kilowatt, subject to working capital adjustments. The 745 megawatt, combined-cycle, gas-fired power plant is located in Londonderry, New Hampshire, about 45 miles northwest of Boston.
“This accretive transaction represents an attractive opportunity for Calpine to build upon our track record of value-enhancing portfolio administration,” said Calpine’s President and Chief Executive Officer Thad Hill. “With the addition of Granite Ridge, our footprint in New England will comprise about 2,000 megawatts of reliable and environmentally responsible generation resources, making us a meaningful supplier in one of the nation’s leading wholesale power markets.”
Granite Ridge is located in ISO-New England, where tightening market conditions have resulted in capacity revenues that will improve substantially over the next three years. The power plant, which commenced commercial operation in 2003, features two Siemens 501G combustion turbines, two heat recovery steam generators and one steam turbine.
Calpine Corporation, a wholesale power generation company, owns and operates natural gas-fired and geothermal power plants in North America. It operates natural gas-fired combustion turbines and renewable geothermal conventional steam turbines.
Shares of Mallinckrodt PLC (NYSE:MNK), inclined 0.91% to $65.58, during its last trading session.
Mallinckrodt plc, declared that data from a pilot study for its H.P. Acthar Gel (repository corticotropin injection) will be presented at the American College of Rheumatology (ACR) 2015 Annual Meeting to be held November 7-11 in San Francisco.
The company-sponsored pilot study, titled “Repository Corticotropin Injection (H.P. Acthar Gel) Attenuates Disease Activity in Patients with Persistently Active Systemic Lupus Erythematosus (SLE) Requiring Corticosteroids,” was an eight-week, double-blind, randomized, placebo-controlled study that assessed clinical efficacy of repository corticotropin injection in patients with persistently active SLE despite moderate dose corticosteroids. An open label extension of this study is ongoing. Acthar is approved by the U.S. Food and Drug Administration for use during an exacerbation or as a maintenance therapy in select patients with SLE.
Mallinckrodt Public Limited Company develops, manufactures, markets, and distributes specialty pharmaceutical products and medical imaging agents worldwide. The company operates through two segments, Specialty Pharmaceuticals and Global Medical Imaging.
Finally, EXCO Resources Inc (NYSE:XCO), ended its last trade with -1.94% loss, and closed at $1.01.
EXCO Resources, declared that it will be releasing third quarter 2015 results on Tuesday, October 27, 2015, after market close.
EXCO will host a conference call on Wednesday, October 28, 2015, at 9:00 a.m. (Central Time) to discuss the contents of this release and respond to questions.
EXCO Resources, Inc., an independent oil and natural gas company, engages in the acquisition, exploration, exploitation, development, and production of onshore oil and natural gas properties with a focus on shale resource plays in the United States.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
